Inven2
Overview
Inven2 is a Norwegian technology transfer office that commercializes research from the University of Oslo and Oslo University Hospital by creating and investing in spin-off companies primarily in the healthcare and life sciences sectors.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Tribune Therapeutics | Mar 2025 | Series A | Co-investor |
| Serca Pharmaceuticals | Jul 2019 | VC Round | Co-investor |
| ProfMOF AS | Jun 2015 | Seed | Co-investor |
| OstomyCure AS | Jul 2026 | Early Funding | Co-investor |
| Respinor AS | Sep 2016 | Seed | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Inven2 based?
Inven2 is headquartered in Oslo, Norway.
When was Inven2 founded?
Inven2 was founded in 2010.
How many portfolio companies does Inven2 have?
Inven2 has 5 portfolio companies in Caplight's dataset.
What are some companies in Inven2's portfolio?
Portfolio companies visible on Caplight include Tribune Therapeutics, Serca Pharmaceuticals, ProfMOF AS, OstomyCure AS, Respinor AS.
What was Inven2's most recent investment shown here?
Inven2's most recent investment in this portfolio sample was in OstomyCure AS in 2026.
What sectors does Inven2 focus on?
Inven2 focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Energy & Sustainability.
What company stages does Inven2 focus on?
Inven2 typically invests at the Early stage.